In cases of complete LOF mutations in MC4R , the receptor becomes nonfunctional, rendering agonists ineffective
Sublingual (under-the-tongue) GLP-1 agonists, such as semaglutide, represent a novel approach, promising similar benefits to injectable versions without the need for needles
However, GLP-1 trends are reshaping diabetes & obesity care with real-world data on adoption, outcomes & future drugs in 2025, according to the HealthVerity Blog
glucagon like peptide 1 analogs market is experiencing significant growth, driven by the rising adoption of drugs like Ozempic and Wegovy for type 2 diabetes and obesity
While multi-drug treatments can be effective, evidence supporting their combined use remains limited
Patients had a mean age of 55 years and 51% were men